WO2020231407A1 - Eltrombopag dosing regimen - Google Patents

Eltrombopag dosing regimen Download PDF

Info

Publication number
WO2020231407A1
WO2020231407A1 PCT/US2019/032171 US2019032171W WO2020231407A1 WO 2020231407 A1 WO2020231407 A1 WO 2020231407A1 US 2019032171 W US2019032171 W US 2019032171W WO 2020231407 A1 WO2020231407 A1 WO 2020231407A1
Authority
WO
WIPO (PCT)
Prior art keywords
eltrombopag
tapering
dose
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/032171
Other languages
English (en)
French (fr)
Inventor
Miona STANKOVIC
Nichola COOPER
Waleed GHANIMA
Francesco ZAJA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharmaceuticals Corp
Original Assignee
Novartis Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP19737274.1A priority Critical patent/EP3968984A1/en
Priority to PCT/US2019/032171 priority patent/WO2020231407A1/en
Priority to CA3140137A priority patent/CA3140137A1/en
Priority to JP2021568408A priority patent/JP2022537883A/ja
Priority to IL288078A priority patent/IL288078A/en
Priority to AU2019445762A priority patent/AU2019445762A1/en
Priority to KR1020217040929A priority patent/KR20220035036A/ko
Priority to US17/611,012 priority patent/US20220313663A1/en
Application filed by Novartis Pharmaceuticals Corp filed Critical Novartis Pharmaceuticals Corp
Priority to MX2021013971A priority patent/MX2021013971A/es
Publication of WO2020231407A1 publication Critical patent/WO2020231407A1/en
Anticipated expiration legal-status Critical
Priority to JP2023166306A priority patent/JP2023182667A/ja
Priority to AU2023274065A priority patent/AU2023274065A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to a method of treating immune thrombocytopenia (ITP), especially chronic ITP, by administering eltrombopag or a pharmaceutically acceptable salt thereof to a patient.
  • ITP immune thrombocytopenia
  • the method relates to the discontinuation of administration of eltrombopag or a pharmaceutically acceptable salt thereof while remaining a treatment-free remission after eltrombopag discontinuation.
  • the method further relates to administering eltrombopag at a tapering regimen while remaining a remission.
  • Platelets are necessary for blood clotting. When platelet numbers are very low a patient is at risk of bleeding, hemorrhage, or death from hemorrhage. ITP is an autoimmune disorder characterized by transient or persistent decrease in platelet count with varied degree of bleeding. Eltrombopag is a highly effective treatment of ITP. It is used for long-term, even lifelong treatment. Long-term treatment with eltrombopag impends substantial costs and is associated with tolerability and compliance issues.
  • the invention relates to a method of treating immune thrombocytopenia (ITP) comprising administering eltrombopag or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein
  • eltrombopag or a pharmaceutically acceptable salt thereof is administered at an initial dose until a complete response is achieved
  • the present invention provides a method of treating immune thrombocytopenia (ITP) comprising administering eltrombopag or a pharmaceutically acceptable salt thereof to a patient in need thereof, comprising
  • c. optionally administering a lower dose of eltrombopag or a pharmaceutically
  • the present invention provides eltrombopag or a pharmaceutically acceptable salt thereof for use in the treatment of ITP comprising administering eltrombopag or a
  • ITP refers to chronic ITP.
  • eltrombopag or a pharmaceutically acceptable salt is present in the form of its bis-monoethanolamine (bis-olamine) salt.
  • the initial dose is 100 mg, 75 mg, 50 mg, or 25 mg daily, suitably 50 mg daily.
  • a complete response is achieved when the platelet count of said patient is at least 50'000/ml_, at least 60'000/mL, at least 70'000/ml_, at least 80'000/ml_, at least 90'000/mL, or at least 100'000/mL, suitably at least 100'000/mL.
  • the consolidation phase is at least one month, one month, at least two months, or two months, suitably two months.
  • the platelet count of said patient is at least 50'000/ml_, at least 60'000/mL, at least 70'000/mL, or at least 80'000/mL, or at least 100'000/mL, suitably at least 70'000/mL.
  • patient achived complete response is in the absence of bleeding as well.
  • the tapering regimen comprises one or more tapering doses, wherein there is a decrement between two adjacent tapering doses.
  • the tapering regimen comprises one, two, three, or four tapering doses.
  • the last tapering dose of the tapering regimen is 25 mg daily, 12.5 mg daily, or 25 mg every other day.
  • the initial dose is 100 mg daily
  • the first tapering dose is 75 mg daily
  • the second tapering dose is 50 mg daily
  • the third tapering dose is 25 mg daily
  • optionally the fourth tapering dose is either 12.5 mg daily or 25 mg every other day.
  • the initial dose is 75 mg daily
  • the first tapering dose is 50 mg daily
  • the second tapering dose is 25 mg daily
  • optionally the third tapering dose is either 12.5 mg daily or 25 mg every other day.
  • the initial dose is 50 mg daily
  • the first tapering dose is 25 mg daily
  • the second i tapering dose is either 12.5 mg daily or 25 mg every other day.
  • the initial dose is 25 mg daily and the tapering dose is either 12.5 mg daily or 25 mg every other day.
  • each tapering dose is administered for a period of one week, two weeks, three weeks, or four weeks, suitably two weeks. Said period can be of different lengths for each tapering dose.
  • the platelet count of said patient is at least 20'000/mL, at least 30'000/mL, at least 40,000/mL, or at least 50,000/mL, suitably at least 30'000/mL.
  • patient achived complete response is in the absence of bleeding as well.
  • treatment-free remission is achieved when the platelet count of said patient is at least 20'000/mL, at least 30'000/mL, at least 40,000/mL, or at least 50,000/mL, suitably at least 30'000/mL.
  • patient achived complete response is in the absence of bleeding as well.
  • treatment-free remission is maintained for at least 1 month, at least 3 months, at least 6 months, at least 1 year, between 1 and 12 months, between 3 and 12 months, between 6 and 12 months, between 12 and 18 months, or between 12 and 24 months.
  • treatment-free remission is achieved when a platelet count of at least 30'000/mL is maintained in the absence of bleeding, i.e. no bleeding adverse event, or in the absence of use of any rescue therapy, e.g. intravenous
  • a treatment of ITP with eltrombopag or a pharmaceutically acceptable salt thereof can be resumed at least 1 month, at least 3 months, at least 6 months, or at least 1 year after the treatment-free remission status is lost.
  • the resumption of treatment comprises the step of administering eltrombopag or a pharmaceutically acceptable salt thereof at the same dose as the initial dose.
  • the resumption of treatment comprises the step of administering eltrombopag or a pharmaceutically acceptable salt thereof at a dose that is lower than the initial dose.
  • “Lower than the initial dose” is understood here as either eltrombopag or a pharmaceutically acceptable salt thereof being administered at a lower dose per administration, or the interval between each administration being longer while the dose unchanged, or both.
  • the resumption of treatment comprises the step of administering eltrombopag or a pharmaceutically acceptable salt thereof at a dose at least 25% or at least 50% lower than the initial dose.
  • the resumption of treatment comprises the step of administering eltrombopag or a pharmaceutically acceptable salt thereof at a dose 25 mg less than the initial dose.
  • the resumption of treatment comprises the step of administering eltrombopag or a pharmaceutically acceptable salt thereof every other day.
  • the resumption of treatment comprises the step of administering eltrombopag or a pharmaceutically acceptable salt thereof at a dose of 25 mg daily.
  • the resumption of treatment comprises the step of administering eltrombopag or a pharmaceutically acceptable salt thereof at a dose of 12.5 mg daily, especially for patients who are of East Asian ancestry.
  • eltrombopag or a pharmaceutically acceptable salt thereof can be administered in combination with steroids.
  • eltrombopag can be administered in combination with dexamethasone.
  • eltrombopag or a pharmaceutically acceptable salt thereof is administered as a first line treatment.
  • eltrombopag or a pharmaceutically acceptable salt thereof is administered as a second line treatment.
  • eltrombopag or a pharmaceutically acceptable salt thereof is administered to patients who are ITP naive patient. In another embodiment of the present invention eltrombopag or a pharmaceutically acceptable salt thereof is administered to patients who are refractory or relapsed after first-line steroids.
  • eltrombopag or a pharmaceutically acceptable salt thereof is administered to an ITP patient whose platelet count is less than 30'000/mL.
  • eltrombopag or a pharmaceutically acceptable salt thereof is administered to patients who relapsed following an initial response to a first-line course of steroid therapy, i.e. steroid-relapsed or steroid-refractory, with or without intravenous immunoglobulin used as a rescue therapy.
  • a first-line course of steroid therapy i.e. steroid-relapsed or steroid-refractory
  • first line steroid therapy is defined as: prednisone/prednisolone 0.5 to 1 mg/kg/day for a minimum of 2 weeks, or minimum of 1 course of high-dose dexamethasone 20-40 mg/day for consecutive 4 days with or without intravenous immunoglobulin (used as rescue therapy), wherein maximum exposure to high dose steroids treatment (steroids tapering time excluded) is limited to 4 weeks of high dose prednisone/prednisolone or 3 courses of high-dose dexamethasone, wherein overall exposure to steroids less than 3 months, including the period of dose tapering.
  • eltrombopag is administered to newly diagnosed primary ITP patients, wherein the time from diagnosis is within 3 months, with a platelet count less than 30'000/mL and a need for treatment, wherein optionally patients were treated with intravenous immunoglobulin 14 days before eltrombopag administration or with any ITP-directed therapy 3 days before eltrombopag administration.
  • newly diagnosed primary ITP patients start the treatment consisting of dexamethasone 40 mg/day for 4 consecutive days (days 1 - 4) and eltrombopag at a starting dose of 50 mg QD beginning at day 1.
  • the dose after initiating eltrombopag at day 1 , the dose must be adjusted by 25 mg increments to a maximum dose of 75 mg QD if the platelet count remains ⁇ 50'000/mL following 2 weeks of therapy.
  • eltrombopag treatment is continued with the minimal dosage necessary to achieve and maintain a platelet count > 50'000/mL for the duration of the consolidation phase.
  • the consolidation phase is about 20 to 22 weeks long.
  • the consolidation phase is followed by a tapering phase.
  • the tapering phase is about 4 to 6 weeks.
  • the decrease in dose during the tapering phase will be performed by 25 mg reductions every 2 weeks, meaning that a next reduction will be carried out within 2 weeks until treatment discontinuation.
  • dexamethasone induces a treatment-free response.
  • eltrombopag induces a complete response at least once by week 4.
  • eltrombopag increases the platelet count from baseline for 1 , 2, 4, 12, 26 and 52 weeks.
  • Numerical values stated herein are to be understood as approximate values. This generally includes an acceptable degree of error for the value measured, due to the nature or precision of the measurements, and/or any underlying biological/chemical/physical fluctuations. Exemplary degrees of error are within 20%, typically, within 10%, and more typically, within 5% of a given value.
  • the actual value can vary by up to 20% from the stated amount. This recognizes that first, the precise amount of a measured platelet count may differ from the actual platelet number in the blood stream due to technical limitations of the method of measuring, and second, it recognizes that the platelet count can vary, fluctuate, or oscillate in a patient for various reasons and individual outlying measurements should not affect the overall assessment of a platelet count and conclusions drawn from it.
  • Platelet count may vary, fluctuate, or oscillate between measurements or can be imprecise due to limitations of the measuring methods. Therefore, a 20% variation, a 10% variation, or a 5% variation from any platelet count value stated herein should be tolerated.
  • the frequency of the measurements can be adjusted by the treating physician.
  • the platelet count is measured once per day, every other day, once per week, once every other week, once per month, once every other month, or once every 6 months.
  • the platelet count is first measured weekly, and once a stable platelet count is reached, the platelet count is measured monthly. The platelet count can be measured prior to initiation of the treatment with
  • “Complete response” or “complete remission” is achieved when a platelet count reaches a defined level.
  • the defined level is typically understood when the platelet count is at least 70'000/ml_, at least 80'000/mL, at least 90'000/mL, at least 100'000/mL, at least 1 10'000/mL, or at least double or at least triple the baseline platelet count of the same patient. In a particular embodiment the defined level is at least 100'000/mL.
  • consolidation phase refers to the time period during which the platelet count is maintained above a defined value, which can be lower than that defined level for a complete response.
  • said level is least 50'000/mL, at least 60'000/mL, at least 70'000/mL, or at least 80'000/mL. In a particular embodiment said level is at least 70'000/mL.
  • the consolidation phase is at least one month, one month, at least two months, or two months. In a particular embodiment the consolidation phase is two months.
  • tapering regimen refers to a dosing regimen consisting of one, two, three or four tapering d doses, wherein the tapering dose is reduced stepwise, i.e. each dose is lower than its preceding dose. There can be one, two, thee, or four steps of dose reductions. In some embodiments each tapering dose is given during a period of one week, two weeks, three weeks, or four weeks. In another embodiment, each tapering dose is given for a different duration, e.g. the first tapering dose is given for 2 weeks and the second one for 4 weeks. In a particular embodiment a tapering dose is given during a period of two weeks. The dose decrement can be a certain percentage, e.g.
  • the platelet count is maintained at least 20'000/mL, at least 30'000/ml_, at least 40'000/mL, or at least 50'000/mL during the tapering regimen. In a particular embodiment the platelet count is at least 30'000/mL during the tapering regimen.
  • dose refers to a certain amount of eltrombopag given at a certain frequency, e.g.
  • doses are daily doses.
  • the term "initial dose” refers to the dose the patient is given to achieve a complete response.
  • a particular initial dose is 50 mg daily.
  • a reduced dose of 25 mg daily is particular for patients who are of East Asian ancestry, e.g. Chinese, Japanese, Taiwanese, or Korean.
  • the initial dose can be changed according to the response of the patient.
  • the dose can be increased, e.g. to 75 mg or 100 mg, if the response is too weak, e.g. platelet count decreases, does not increase, or increases too slowly.
  • the dose can be reduced, e.g. to 25 mg, if the response is too strong, e.g. platelets increase too quickly.
  • the initial dose can be adjusted one or multiple times to reach the optimal initial dose for a patient.
  • the initial dose is the dose that is administered before initiating a tapering regimen.
  • tapering dose refers to a dose that is administered after the patient had been treated with an initial dose. A tapering dose is lower than an initial dose.
  • discontinue and discontinuation refer to the end of the treatment.
  • the drug is not given to the patient anymore during a period of time. This period can either be a drug holiday, after which the drug administration is resumed, or it can be a final discontinuation. If drug administration is resumed the dose can be the same as the previous initial dose or less.
  • treatment-free remission refers to a remission that remains after discontinuation of the administration of eltrombopag or a pharmaceutically acceptable salt thereof.
  • the platelet count of a patient during treatment-free remission is at least 20'000/mL, at least 30'000/mL, at least 40,000/mL, or at least 50,000/mL, suitably at least 30'000/mL. Loss of remission response is achieved when the platelet count drops below 30'000/mL and/or a bleeding event occurs for a period of at least 2 weeks or at least one month.
  • Example 1 A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (TAPER)
  • TAPER first-line steroids
  • the purpose of this trial is to assess the ability of eltrombopag to induce sustained treatment- free remission in ITP subjects who failed to respond or have relapsed after an initial treatment with steroids.
  • the primary objective is to assess the ability of eltrombopag to induce sustained remission by month 12 in ITP subjects who relapsed or failed to respond to first-line steroid treatment.
  • the primary endpoint is the proportion of subjects with sustained remission by month 12, where sustained remission is defined as:
  • the main secondary objectives are:
  • Endpoint Number (%) of subjects who maintain a platelet count > 30'000/mL from the first time of reaching that level to month 3, 6, 9, 12 and end-of-study without bleeding and no rescue therapy.
  • the study is designed to include adult subjects with primary ITP who have failed to respond or who relapsed following an initial response to a first-line course of steroid therapy (steroid- relapsed or steroid-refractory) with or without ⁇ intravenous immunoglobulin (IVIG) used as a rescue
  • Platelet count is ⁇ 30'000/mL and assessed as needing treatment (per physician’s discretion).
  • First line of steroid therapy will be defined as: prednisone/prednisolone 0.5 to 1 mg/kg/day for a minimum of 2 weeks, or minimum of 1 course of high-dose dexamethasone 20- 40
  • ITP subjects previously treated with any ITP second-line therapies, thrombopoietin receptor agonists for ITP, except steroids / IVIG.
  • Subjects will be treated with eltrombopag 50 mg daily (QD) for 2 weeks to reach a target platelet count of > 100'000/mL. For those subjects who do not achieve the target platelet count within 2 weeks, the dose of eltrombopag will be increased to 75 mg QD. Those subjects who have not reached the target platelet count > 100'000/mL after being treated with eltrombopag 75 mg/day will continue on eltrombopag until month 12. Treatment with eltrombopag will be continued at the minimal dosage necessary to achieve and maintain a platelet count around 100'000/mL for 2 months.
  • QD eltrombopag 50 mg daily
  • CR complete response
  • the duration of tapering will be individualized and depend upon starting dose and response of the subject: decreases in dose will be performed by 25 mg reductions every 2 weeks. If platelet counts are stable, the next reduction should be carried out within 2 weeks, with dosing at 25 mg on alternate days for 2 weeks until treatment is totally discontinued.
  • a reduced initial dosage of 25 mg QD is recommended for subjects of Asian ancestry.
  • the dose of eltrombopag in subjects with Asian ancestry will be reduced to account for the lower eltrombopag clearance (CL/F) observed in these subjects compared to the non-Asian population. Therefore, drug tapering for subjects with Asian ancestry will be done in 12.5 mg decrements every second week.
  • Platelet count will be performed at screening visit 1 to assess the eligibility of the subject.
  • Hematology including platelet counts will be assessed at week 1/day 1 and weekly during the first 8 weeks of treatment. Based on subject response, hematology will be performed biweekly thereafter until the end of treatment. Additional assessments of platelet count may be performed more frequently than the biweekly schedule if needed in accordance with the clinical judgment of the investigator. Bleeding events will be assessed at each visit.
  • the purpose of this trial is to assess the ability of eltrombopag to induce sustained treatment- free
  • the primary objective is to assess the ability of eltrombopag to induce sustained response off treatment at month 6 in ITP subjects who were treated with second line eltrombopag and previously achieved CR.
  • the primary endpoint is the proportion of subjects with sustained response off treatment at month 6 wherein sustained response off treatment is defined as:
  • the study is designed to include adult subjects with ITP who failed to respond or who relapsed after first-line steroid treatment and are on treatment with eltrombopag. Platelet count is > 100'000/mL and stable (above 70'000/mL) for 2 months.
  • Subjects will begin stepwise reduction of the eltrombopag dose on day 1. In case of relapse they will be re-treated with eltrombopag. Relapse is defined as platelet count ⁇ 30'000/mL. Treatment will be with 50 mg - 75 mg eltrombopag until end-of-study. Subjects in sustained response off treatment at month 6 will enter a 1 year follow-up period. Sustained response off treatment is defined as:
  • the study includes a second arm which are patients on second line steroids.
  • the steroids will be stopped on day 1 and there will be re-treatment with steroids or eltrombopag after relapse.
  • the timing and endpoints of the second arm are the same and subjects in sustained response off treatment at month 6 will also enter a 1 year follow-up period.
  • Example 3 A Phase I I, randomized (1:1) open label study to assess the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone, as first-line treatment in adult patients with newly diagnosed immune thrombocytopenia Purpose
  • first-line therapy can induce superior long-term remission rates.
  • Spontaneous remissions occur in about 10% of adult patients.
  • Traditional first-line agents achieve high initial response rates (70-80%) within 2 to 14 days, but have suboptimal durability.
  • Sustained platelet responses after discontinuation of corticosteroid occurs in ⁇ 30% of patients within the first year. Approximately 50% of patients have relapsed by 6 months, with an additional 25% relapsing beyond 1 year. Long-term administration of corticosteroids is limited by the development of side effects.
  • the aim is to reduce chronic steroid use (high doses of steroids associated with morbidity) and to improve treatment-free remission.
  • This study is designed to include newly diagnosed adult primary ITP-patients (time from diagnosis within 3 months) with a platelet count ⁇ 30'000/mL and a need for treatment.
  • treatment with intravenous immunoglobulin is permitted 14 days before randomization (alternative: any ITP-directed therapy 3 days before randomization might be permitted). Otherwise, previous history of treatment for ITP is an exclusion criterium.
  • the primary objective is to assess the ability of eltrombopag in combination with
  • Treatment-free response is defined as maintaining a platelet count > 30'000/mL after treatment discontinuation in the absence of bleeding > Grade II or use of any rescue medication.
  • Main secondary objectives are:
  • Endpoint Median duration of treatment-free response calculated from the time of treatment discontinuation until platelet count ⁇ 30'000/mL or bleeding > Grade II or use of rescue therapy.
  • Endpoint Rates of patients achieving a treatment free response at week 78. • Assess the ability of eltrombopag to induce overall response by week 4. Endpoint:
  • Endpoint Absolute and relative change in platelet count from baseline to 1 , 2, 4, 12, 26 and 52 weeks.
  • Arm A is eltrombopag in combination with dexamethasone and Arm B is dexamethasone alone.
  • Arm A consists of treatment from day 1 until week 26 including tapering of eltrombopag.
  • Tapering of eltrombopag is either 4 weeks after 22 weeks of induction therapy or 6 weeks after 20 weeks of induction therapy.
  • induction therapy is understood as the total period during which eltrompobag or a pharmaceutically acceptable salt thereof is administered before the dose is reduced.
  • induction therapy includes the period during which patient are treated to achieve complete response and the following period during which patient are treated to maintain the remission (consolidation phase).
  • Treatment consists of dexamethasone 40 mg/day for 4 consecutive days (days 1 - 4) and eltrombopag at a starting dose of 50 mg QD beginning at day 1. After initiating eltrombopag at day 1 , the dose must be adjusted by 25 mg increments to a maximum dose of 75 mg QD if the platelet count remains ⁇ 50'000/mL following 2 weeks of therapy. Eltrombopag treatment is continued with the minimal dosage necessary to achieve and maintain a platelet count > 50'000/mL for the duration of the induction period (until week 20 or week 22) followed by a 4 week or 6 week taper to discontinue eltrombopag. During tapering of eltrombopag, a decrease in dose will be performed by 25 mg reductions every 2 weeks, meaning that a next reduction will be carried out within 2 weeks until treatment discontinuation.
  • Arm B consists of treatment from day 1 until week 12.
  • the treatment consists of 1 - 3 cycles of pulsed dexamethasone 40 mg/day for 4 consecutive days (days 1 - 4) at 4-week intervals.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2019/032171 2019-05-14 2019-05-14 Eltrombopag dosing regimen Ceased WO2020231407A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020217040929A KR20220035036A (ko) 2019-05-14 2019-05-14 엘트롬보팍 투약 요법
CA3140137A CA3140137A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen
JP2021568408A JP2022537883A (ja) 2019-05-14 2019-05-14 エルトロンボパグの投与計画
IL288078A IL288078A (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen
AU2019445762A AU2019445762A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen
EP19737274.1A EP3968984A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen
PCT/US2019/032171 WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen
US17/611,012 US20220313663A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen
MX2021013971A MX2021013971A (es) 2019-05-14 2019-05-14 Regimen de dosificacion de eltrombopag.
JP2023166306A JP2023182667A (ja) 2019-05-14 2023-09-27 エルトロンボパグの投与計画
AU2023274065A AU2023274065A1 (en) 2019-05-14 2023-11-27 Eltrombopag dosing regimen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/032171 WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Publications (1)

Publication Number Publication Date
WO2020231407A1 true WO2020231407A1 (en) 2020-11-19

Family

ID=67211802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/032171 Ceased WO2020231407A1 (en) 2019-05-14 2019-05-14 Eltrombopag dosing regimen

Country Status (9)

Country Link
US (1) US20220313663A1 (cg-RX-API-DMAC7.html)
EP (1) EP3968984A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022537883A (cg-RX-API-DMAC7.html)
KR (1) KR20220035036A (cg-RX-API-DMAC7.html)
AU (2) AU2019445762A1 (cg-RX-API-DMAC7.html)
CA (1) CA3140137A1 (cg-RX-API-DMAC7.html)
IL (1) IL288078A (cg-RX-API-DMAC7.html)
MX (1) MX2021013971A (cg-RX-API-DMAC7.html)
WO (1) WO2020231407A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150148385A1 (en) * 2012-06-29 2015-05-28 Shionogi & Co., Ltd. Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150148385A1 (en) * 2012-06-29 2015-05-28 Shionogi & Co., Ltd. Pharmaceutical composition containing a compound having a thrombopoietin receptor agonistic activity

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Ausschleichung", WIKIPEDIA, 1 November 2022 (2022-11-01), pages 1, XP093068759, [retrieved on 20230731]
ANONYMOUS: "History of Changes for Study: NCT03524612", 2 May 2018 (2018-05-02), XP055656370, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03524612?A=1&B=23&C=merged#StudyPageTop> [retrieved on 20200109] *
BAHAREH GHADAKI ET AL: "Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists : Sustained ITP Remissions after TPO Receptor Agonists", TRANSFUSION., vol. 53, no. 11, 1 November 2013 (2013-11-01), US, pages 2807 - 2812, XP055656200, ISSN: 0041-1132, DOI: 10.1111/trf.12139 *
BUSSEL ET AL: "Paper: Tapering Eltrombopag in Patients with Chronic ITP: How Successful Is This and in Whom Does It Work?", BLOOD, 5 December 2015 (2015-12-05), XP055656399 *
BUSSEL, BLOOD, 2015
BUSSEL, BR. J. HAEMATOL., 2013
CERVINEK, INT. J. HAEMATOL., 2015
GHADAKI, TRANSFUSION, 2013
JOSE RAMON GONZALEZ-PORRAS ET AL: "Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety", THERAPEUTIC ADVANCES IN DRUG SAFETY, vol. 9, no. 6, 11 June 2018 (2018-06-11), pages 263 - 285, XP055656212, ISSN: 2042-0986, DOI: 10.1177/2042098618769587 *
MAHEVAS, BR. J. HAEMATOL., 2014
MANNUSS STEFFEN: "Influence of different methods and anticoagulants on platelet parameter measurement", JOURNAL OF LABORATORY MEDICINE, vol. 44, no. 5, 1 October 2020 (2020-10-01), pages 255 - 272, XP093245389, ISSN: 2567-9430, DOI: 10.1515/labmed-2020-0037
TOMÁS JOSÉ GONZÁLEZ-LÓPEZ ET AL: "Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia : Discontinuation of Eltrombopag in Primary ITP", AMERICAN JOURNAL OF HEMATOLOGY, vol. 90, no. 3, 1 March 2015 (2015-03-01), US, pages E40 - E43, XP055656124, ISSN: 0361-8609, DOI: 10.1002/ajh.23900 *

Also Published As

Publication number Publication date
JP2023182667A (ja) 2023-12-26
AU2019445762A1 (en) 2021-12-09
MX2021013971A (es) 2022-04-01
AU2023274065A1 (en) 2023-12-14
JP2022537883A (ja) 2022-08-31
US20220313663A1 (en) 2022-10-06
IL288078A (en) 2025-01-01
CA3140137A1 (en) 2020-11-19
KR20220035036A (ko) 2022-03-21
EP3968984A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP7295305B2 (ja) ループス腎炎の治療のための改善されたプロトコル
TWI786636B (zh) 用於治療葡萄膜炎及黃斑水腫之包含il6r抗體的組合物與其使用方法
JP2024530954A5 (cg-RX-API-DMAC7.html)
Schiappapietra et al. Glucocorticoids in juvenile idiopathic arthritis
Desideri et al. Evidence-based guidelines for drug dosing in intravitreal injections in silicone oil-filled eyes: Pharmacokinetics, safety, and optimal dosage
US9920131B2 (en) Dosage and administration of anti-EGFR therapeutics
WO2020231408A1 (en) Eltrombopag dosing regimen
JP2021152002A5 (cg-RX-API-DMAC7.html)
US20170224815A1 (en) Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
AU2023274065A1 (en) Eltrombopag dosing regimen
Spies et al. Analyses of similarities and differences in glucocorticoid therapy between rheumatoid arthritis and ankylosing spondylitis—a systematic comparison
JP2024516886A5 (cg-RX-API-DMAC7.html)
McNeil Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity
JP2020172471A (ja) ヒト化抗ヒトcd26抗体を含有する医薬組成物
AU2021260982A1 (en) Dosing regimen for treating a disease modulated by CSF-1R
RU2747193C2 (ru) Композиции, содержащие антитела к il6r, для лечения увеита и макулярного отека, и способы их применения
Delaney et al. Emerging treatments for non-infectious uveitis
Dalton et al. Ranibizumab achieves higher BCVA gains for BRVO in COMRADE-B.
RU2024105814A (ru) Лечение атопического дерматита
RU2023120407A (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r
WO2019231800A1 (en) Anti-cgrp antibodies for treating menstrual-related migraines
TH2001001181A (th) วิธีการสำหรับการบำบัดโรคที่เกี่ยวข้องกับ-tnf
Narayanan et al. Corticosteroids: Triamcinolone, Dexamethasone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19737274

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021568408

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3140137

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019445762

Country of ref document: AU

Date of ref document: 20190514

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20217040929

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019737274

Country of ref document: EP

Effective date: 20211214

WWW Wipo information: withdrawn in national office

Ref document number: 2019737274

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020217040929

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 288078

Country of ref document: IL